Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has emerged as an attractive cytokine that selectively targets cancer cells, however its efficacy has been challenged by a number of resistance mechanisms. Therefore, the current study investigated the potential of dipyridamole to enhance TRAIL efficacy and the probable underlying mechanisms. Dipyridamole dramatically sensitized p53-mutant human cancer cell lines: SW480, MG63 and DU145, to the antitumor activity of TRAIL, as evidenced by enabling TRAIL to efficiently cleave initiator and executioner caspases. Although dipyridamole upregulated both DR4 and DR5 and increased their cell surface expression, RNA interference revealed a preferential dependence on DR5. Moreover, dipyridamole inhibited survivin expression and its important consequences were confirmed by small interfering RNA. Mechanistically, dipyridamole induced transcriptional shutdown of survivin expression accompanying G 1 arrest that was characterized by downregulation of D-type cyclins and cdk6. In addition, a transcriptional mechanism powered by CCAAT/enhancer-binding protein (C/EBP) homologous protein (CHOP) induction was responsible for DR5 upregulation by dipyridamole. Importantly, dipyridamole-induced enhancement of TRAIL efficacy and alterations of protein expression were independent of either protein kinase A or protein kinase G. In conclusion, findings of the present study described novel mechanisms of dipyridamole action and highlighted its promising use as a potential enhancer of TRAIL efficacy.
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNFa superfamily (Wiley et al., 1995) that has drawn a considerable attention recently as an attractive cytokine for cancer therapy. TRAIL targets the extrinsic pathway of apoptosis via interaction with death receptors (DRs). To date, five receptors have been shown to bind TRAIL, of which only two receptors have cytoplasmic death domain that engages apoptotic machinery upon TRAIL binding, and are known as DR4 (TRAIL-R1) and DR5 (TRAIL-R2) (Carlo-Stella et al., 2007) . Interestingly, TRAIL has been shown to selectively induce apoptosis independent of p53 tumor suppressor in a variety of transformed cell lines and exerted a potent antitumor activity against xenografts of various cancers without adversely affecting normal cells (Ashkenazi et al., 1999; Walczak et al., 1999; Altieri, 2003) .
Dipyridamole, a drug that has widely been used as an antiplatelet, was previously reported to increase the cytotoxicity of a number of chemotherapeutic agents on various human cancer cells through increasing intracellular accumulation of cisplatin, methotrexate and 5-fluorouracil metabolites (Kennedy et al., 1986; Sato et al., 1993; Rodrigues et al., 2004) . Additionally, being a well-known nucleoside transport inhibitor, dipyridamole enhanced methotrexate cytotoxicity by preventing thymidine salvage (Van Mouwerik et al., 1987) .
Despite the promising potential of TRAIL, a number of resistance mechanisms compromised its efficacy (Van Geelen et al., 2004) . Therefore, the current study was undertaken to examine the potential of dipyridamole to enhance the tumoricidal activity of TRAIL against p53-mutant human cancer cell lines of different origin, and provided insights into the underlying mechanisms.
Results
Dipyridamole sensitized human cancer cells of different origin to TRAIL-induced apoptosis and upregulated TRAIL DRs Pretreatment of SW480, MG63 and DU145 cells with increasing concentrations of dipyridamole resulted in several folds of enhancement of TRAIL-induced apoptosis ( Figure 1a) . As a starting point for investigation of the underlying mechanisms, immunoblot analysis of DR4 and DR5 expression was performed, and showed their dose-dependent upregulation by dipyridamole in SW480 cells, with no effect on fas-associated death domain (FADD) and c-FLIP L expression (Figure 1b) . Upregulation of DR4 and DR5 was also observed in MG63 and DU145 cells (Figure 1c) . Moreover, dipyridamole enriched the cell surface expression of DR4 and DR5 (Figure 1d ), but not that of TRAIL decoy receptors (data not shown) in SW480 cells.
Upregulation of DR5 preferentially mediated enhancement of TRAIL efficacy by dipyridamole To test whether upregulation of DR4 and DR5 was of functional significance, knockdown of their expression was carried out using small interfering RNA (siRNA) strategy. Although immunoblotting showed marked abrogation of dipyridamole-induced upregulation of DR5 ( Figure 2a ) and DR4 ( Figure 2b ) in SW480 cells, dipyridamole-dependent TRAIL sensitization was partially but significantly abrogated only in response to DR5 knockdown (Figure 2a) . It is worth mentioning that combined knockdown of both DR5 and DR4 was not more effective than DR5 knockdown in reducing dipyridamole-induced enhancement of TRAIL efficacy (Figure 2c ). Similar results were obtained with MG63 cells (Figure 2d ).
Survivin was downregulated by dipyridamole and contributed markedly toward TRAIL sensitization The partial involvement of DR5 in mediating dipyridamole-induced enhancement of TRAIL efficacy prompted us to examine the involvement of other mechanisms. In this regard, immunoblot analysis of the Bcl-2 family in SW480 cells showed that their expression was unaffected by dipyridamole ( Figure 3a) . On the other hand, immunoblot analysis of the inhibitor of apoptosis protein (IAP) family showed a marked suppression of survivin in SW480, MG63 and DU145 cells ( Figure 3a) .
Next, we assessed the contribution of survivin downregulation toward sensitizing cancer cells to TRAIL-induced apoptosis. Knockdown of survivin expression clearly resulted in manifold increases in TRAIL-induced apoptosis of SW480 cells (Figure 3b ), and this was accompanied by enhanced processing of caspase-9 and -3 as a result of relieved inhibitory effect of survivin (Figure 3c ). In the light of recent findings that suggested that caspase-3 and -9 could modulate the complete processing and activation of caspase-8 (Wieder et al., 2001; Pirnia et al., 2002; Aouad et al., 2004) , we hypothesized that survivin downregulation may enhance TRAIL-induced processing of the initiator caspases of the extrinsic apoptotic pathway. Results shown in Figure 3c clearly supported this hypothesis. Additionally, the use of caspase-9 and -3 inhibitors reduced such increased processing of caspase-8 and -10 ( Figure 3c ). Furthermore, under the condition of combined dipyridamole/TRAIL treatment, caspase-3 and -9 inhibitors also reduced dipyridamole-induced enhancement of TRAIL-triggered complete processing of caspase-8 and -10 and accordingly inhibited other downstream events (Figure 3d ).
The contribution of survivin downregulation toward TRAIL sensitization was only apparent upon the initiation of apoptotic signal generation through the extrinsic pathway since interference with this initiation step using recombinant human DR5/Fc chimera or inhibitors of caspase-8 and -10 or the pan caspase inhibitor significantly abrogated caspases processing and TRAIL-induced apoptosis (Figure 3d ).
Dipyridamole induced transcriptional shutdown of survivin associated with G 1 cell cycle arrest Since survivin expression is known to be regulated at transcriptional and post-translational levels (Zhang et al., 2006) , we investigated which of these mechanisms was involved. Dipyridamole treatment downregulated survivin RNA levels in northern blot analysis (Figure 4a ), and significantly suppressed survivin promoter activity (Figure 4b) . Because of the known cell cycle regulation of survivin expression (Li et al., 1998) , cell cycle perturbation by dipyridamole was examined. Dipyridamole induced G 1 cell cycle arrest in SW480, MG63 and DU145 cells, evidenced by reductions in hyperphosphorylation (pp) of retinoblastoma protein (RB) (Figure 4c) . A detailed immunoblot analysis of dipyridamole-induced alterations of the regulatory proteins of the G 1 phase in SW480 cells showed that the expression levels of cyclin D2, cyclin D3 and cyclin-dependent kinase-6 (cdk6) were dose dependently downregulated ( Figure 4d ). In MG63 cells, only cyclin D3 and cdk6 were downregulated (Figure 4e ), whereas in DU145 cells only cyclin D2 and cyclin D3 levels were suppressed (Figure 4e ), while cdk6 was not downregulated (data not shown).
Since dipyridamole has been previously shown to inhibit cAMP-and cGMP phosphodiesterases (Salzman et al., 1972; Clarke et al., 1994) , we examined whether their downstream targets: protein kinase A (PKA) and protein kinase G (PKG), respectively, were involved. Pretreatment of SW480 cells with increasing concentrations of the inhibitors of either PKA or PKG did not correct dipyridamole-induced shutdown of survivin transcription (Figure 4f ), nor the reductions in RB hyperphosphorylation, cyclin D2, cyclin D3 and cdk6 expression levels ( Figure 4g ).
Dipyridamole upregulated DR5 through CHOP induction and enhanced TRAIL efficacy independently of either PKA or PKG To gain insights into the mechanisms underlying DR5 upregulation by dipyridamole in SW480 cells, northern blot analysis showed a dose-dependent upregulation of DR5 RNA level (Figure 5a ). In addition, luciferase assay confirmed dipyridamole-induced transcriptional activation of all DR5 promoter deletion mutants with 301 base pairs (bp) or longer upstream of the transcription initiation site (TIS) (Figure 5b ), but such activation was lost in a shorter construct with 252-bp upstream of the TIS (Figure 5b ), indicating a critical requirement for the 50-bp region between À301 and À252 region of DR5 promoter, which has been previously shown to contain a functional CHOP binding site . This has been further confirmed by using DR5 promoter deletion mutants with either wild-type (pDR5/wtCHOP) or mutated (pDR5/mtCHOP) CHOP binding site, where dipyridamole-induced DR5 promoter activation was abrogated only in the construct with mutated CHOP binding site (Figure 5c ). Both western and northern blots showed upregulation of CHOP protein and RNA levels, respectively, by dipyridamole (Figure 5d ). Moreover, luciferase assay showed that dipyridamole treatment transcriptionally activated CHOP promoter (Figure 5e ). Immunoblot analysis of the time-course expression of DR5 and CHOP revealed that CHOP induction preceded DR5 upregulation (Figure 5f ). The cause-effect relationship between CHOP and DR5 was confirmed through CHOP siRNA, which abrogated dipyridamole-induced DR5 upregulation (Figure 5g) . Furthermore, the dose-dependent induction of CHOP by dipyridamole was also seen in both MG63 and DU145 cell lines (Figure 5h ). Importantly, neither PKA nor PKG was involved in dipyridamole-induced CHOP and DR5 upregulation (Figure 5i ) as well as in the enhancement of TRAIL efficacy (Figure 5j ).
Discussion
The current study described for the first time the enhancement of TRAIL tumoricidal activity against a number of p53-mutant human cancer cell lines upon ) then 75 mM of dipyridamole (Dip) for 24 h, followed by TRAIL (10 ng ml
À1
) treatment for additional 14 h. Asterisk indicates a statistically significant difference at Po0.05.
Dipyridamole enhances TRAIL efficacy AE Goda et al combined treatment with dipyridamole. Although we have presented results obtained from SW480, MG63 and DU145 cell lines, dipyridamole could successfully overcome TRAIL resistance of many other p53-mutant human cancer cell lines of different origin including HT29, SW620, DLD-1, HCT15 (colorectal carcinoma), SAOS-2 (osteosarcoma) and Jurkat (T-cell acute lymphoblastic leukemia) (data not shown), strongly suggesting the generalized nature of the TRAILsensitizing potential of dipyridamole.
Characterization of the mechanisms underlying this enhancement revealed two novel findings of dipyridamole treatment: (1) upregulation of TRAIL DRs, and (2) downregulation of survivin, which are well-known regulators of TRAIL-triggered apoptotic signals (Azuhata et al., 2006; Carlo-Stella et al., 2007) . We have also shown that DR5 contributed preferentially toward dipyridamole-induced TRAIL sensitization, corroborating the findings reported previously (Kelley et al., 2005) .
The present study described a novel mechanism of dipyridamole-induced G 1 arrest in human cancer cells that involved downregulation of a number of key regulators of cell cycle (Lin et al., 2001) , that is, cyclin D2, cyclin D3 and cdk6, but differed from its previously reported mechanism (Hung et al., 2001) . Despite the fact that cyclin D3 downregulation was a common event among SW480, MG63 and DU145 cells treated with dipyridamole, cyclin D3 siRNA was insufficient to induce a marked change in cell cycle of SW480 cells (data not shown) comparable to that induced by dipyridamole treatment, suggesting that downregulation of cyclin D2 and/or CDK6 was required along with cyclin D3 downregulation to cooperatively mediate dipyridamole-induced G 1 arrest in a cell line-dependent manner. Furthermore, unlike previous reports (Hung et al., 2001; Zhuplatov et al., 2006) , results of the current study precluded the contribution of neither PKA nor PKG into dipyridamole-induced G 1 arrest, and this discrepancy could be attributed to differences among cell lines examined. Li et al. (1998) have described that the lowest expression levels of survivin occurred during the G 1 phase. Later, a number of reports have shown that induction of G 1 arrest per se was sufficient to trigger survivin downregulation (Fulda and Debatin, 2004; Lu et al., 2005) . Taken together, these findings reinforced the proposed mechanism underlying dipyridamoleinduced survivin downregulation, at least in part, through the induction of G 1 cell cycle arrest.
With regard to the mechanism of transcriptional activation of DR5 promoter by dipyridamole, Sp1 was excluded because the shortest DR5 luciferase construct examined (pDR5/-252) had two wild-type Sp1 binding sites, but was not activated. Moreover, a DR5 promoter deletion mutant having mutated nuclear factor-kappa B (NF-kB) binding site retained its activity in luciferase assay in response to dipyridamole treatment (data not shown), precluding the involvement of NF-kB. Additionally, p53-independency was confirmed since all activated DR5 promoter deletion mutants examined lacked a wild-type p53 binding site. The dependency of the transcriptional activation of DR5 promoter on CHOP was confirmed in SW480 cells through CHOP siRNA, similar to a previous study , and it would be anticipated to be the operating mechanism in MG63 and DU145 cells since CHOP was also dose dependently upregulated by dipyridamole in these cell lines. Moreover, we have demonstrated a transcriptional mechanism to be responsible for CHOP induction by dipyridamole and this is in line with a previous report (Thompson and Sistare, 2003) . Importantly, CHOP and DR5 upregulation as well as the enhancement of Dipyridamole ( TRAIL efficacy by dipyridamole were independent of either PKA or PKG.
The novel mechanisms of dipyridamole action described in the current study explained, at least in part, how dipyridamole amplified the intensity of TRAIL-triggered apoptotic signals and provided a rationale for its potential use as an enhancer of TRAIL tumoricidal activity. 
